Achaogen (NASDAQ:AKAO)‘s stock had its “buy” rating restated by Mizuho in a report issued on Wednesday, January 3rd. They presently have a $28.00 target price on the biopharmaceutical company’s stock. Mizuho’s price objective indicates a potential upside of 125.44% from the stock’s current price.
Other research analysts have also recently issued research reports about the company. Stifel Nicolaus lowered their price objective on Achaogen from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, November 9th. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Achaogen in a research note on Thursday, November 9th. Guggenheim started coverage on Achaogen in a research note on Tuesday, October 24th. They set a “buy” rating and a $17.00 price objective for the company. SunTrust Banks lowered their price objective on Achaogen to $27.00 and set a “buy” rating for the company in a research note on Wednesday, January 3rd. Finally, ValuEngine upgraded Achaogen from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Two research analysts have rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $25.62.
Achaogen (NASDAQ:AKAO) traded up $0.76 on Wednesday, hitting $12.42. The stock had a trading volume of 1,258,239 shares, compared to its average volume of 1,853,930. The stock has a market cap of $520.17, a PE ratio of -3.70 and a beta of 1.35. The company has a current ratio of 6.99, a quick ratio of 6.99 and a debt-to-equity ratio of 0.08. Achaogen has a 52 week low of $10.24 and a 52 week high of $27.79.
Achaogen (NASDAQ:AKAO) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.13). The firm had revenue of $0.58 million during the quarter, compared to analysts’ expectations of $2.09 million. Achaogen had a negative net margin of 593.61% and a negative return on equity of 80.44%. The company’s revenue for the quarter was down 96.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.41) EPS. sell-side analysts predict that Achaogen will post -3.06 EPS for the current fiscal year.
In other news, major shareholder Robert W. Duggan bought 95,012 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were bought at an average cost of $11.13 per share, for a total transaction of $1,057,483.56. Following the completion of the transaction, the insider now owns 5,602,752 shares of the company’s stock, valued at $62,358,629.76. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Robert W. Duggan bought 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 3rd. The stock was purchased at an average price of $10.89 per share, for a total transaction of $163,350.00. Following the completion of the transaction, the insider now directly owns 5,617,752 shares of the company’s stock, valued at approximately $61,177,319.28. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 160,012 shares of company stock valued at $1,796,334. Corporate insiders own 8.36% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Marcus Capital LLC purchased a new stake in Achaogen during the second quarter valued at approximately $1,769,000. Point72 Asset Management L.P. raised its position in Achaogen by 55.7% during the third quarter. Point72 Asset Management L.P. now owns 2,255,899 shares of the biopharmaceutical company’s stock valued at $35,982,000 after purchasing an additional 806,899 shares during the period. Artal Group S.A. raised its position in Achaogen by 25.0% during the third quarter. Artal Group S.A. now owns 250,000 shares of the biopharmaceutical company’s stock valued at $3,988,000 after purchasing an additional 50,000 shares during the period. Bank of New York Mellon Corp raised its position in Achaogen by 68.5% during the second quarter. Bank of New York Mellon Corp now owns 191,670 shares of the biopharmaceutical company’s stock valued at $4,165,000 after purchasing an additional 77,887 shares during the period. Finally, TimesSquare Capital Management LLC raised its position in Achaogen by 106.7% during the second quarter. TimesSquare Capital Management LLC now owns 1,088,300 shares of the biopharmaceutical company’s stock valued at $23,649,000 after purchasing an additional 561,700 shares during the period. Institutional investors own 85.74% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/11/achaogen-akao-given-buy-rating-at-mizuho.html.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.